Loading...
•
Dec 31, 2022
Teva Q4 2022 Earnings Report
Teva's Q4 2022 earnings were reported, showing a revenue of $3.9 billion and a GAAP diluted loss per share of $(1.10).
Key Takeaways
Teva Pharmaceutical Industries Ltd. reported Q4 2022 revenues of $3.9 billion, a decrease of 5% in U.S. dollars or an increase of 1% in local currency terms compared to Q4 2021. GAAP diluted loss per share was $(1.10), while non-GAAP diluted EPS was $0.71. Cash flow generated from operating activities was $973 million, and free cash flow was $1,140 million.
Revenues in the fourth quarter of 2022 were $3,884 million, a decrease of 5% in U.S. dollars or an increase of 1% in local currency terms, compared to the fourth quarter of 2021.
GAAP diluted loss per share in the fourth quarter of 2022 was $(1.10), compared to $(0.14) in the fourth quarter of 2021.
Non-GAAP diluted EPS in the fourth quarter of 2022 was $0.71, compared to $0.77 in the fourth quarter of 2021.
Cash flow generated from operating activities during the fourth quarter of 2022 was $973 million, compared to $456 million in the fourth quarter of 2021.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Teva provided its 2023 business outlook, with revenues expected to be $14.8 - $15.4 billion, adjusted EBITDA of $4.5 - $4.9 billion, non-GAAP diluted EPS expected to be $2.25 - $2.55, and free cash flow expected to be $1.7 - $2.1 billion.
Challenges Ahead
- Volatile swings in FX can negatively impact revenue and income
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...